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Percutaneous absorption was studied in patients following topical application of betame-
thasone 17-benzoate cream and gel with occlusion by means of a sensitive and specific 
radioimmunoassay method. Concentrations of betamethasone 17 -benzoate in plasma were 
between 0.3 and 5 ng/ml , indicating approximately 0.05 to 0.3% of the steroid applied to the 
skin was detected in plasma. Plasma betamethasone 17 -benzoate levels increased in 
proportion to the amount of the steroid applied to the skin. High correlation between plasma 
betamethasone 17 -benzoate levels and percent inhibition of plasma cortisol was also 
observed. Approximately 3 ng/ml levels of betamethasone 17-benzoate in plasma induced 
90% inhibition of plasma cortisol. The data suggest that betamethasone 17 -benzoate in gel 
base was more readily absorbed than in cream base. 
The value of topical corticosteroids in the treat-
ment of various skin diseases has been well estab-
lished. Information about the distribution of ste-
roids into various body compartments has been 
obtained with the use of labeled compounds which 
permit the measurement of radioactivity in body 
fluids [1,2]. However, relatively little is known 
about plasma levels of these compounds when they 
are applied to the skin of patients. In this study we 
report plasma betamethasone 17 -benzoate levels in 
patients following topical application of betame-
thasone 17-benzoate cream and gel with occlusion 
determined by the use of a sensitive and specific 
radioimmunoassay method [3]. Correlation 
between plasma betamethasone 17 -benzoate levels 
and inhibition of plasma cortisol is also described. 
MATERIALS AND METHODS 
Complete details of materials and the betamethasone 
17 -benzoate radioimmunoassay procedures have been 
described recently [3] . They may be briefly summarized: 
[l ,2- 3H]Betamethasone 17-benzoate (0 .8 Ci/mmole) was 
synthesized in our laboratory [4]. Its purity was more 
than 99 % as determined by thin-layer chromatography. 
Betamethasone 17 -benzoate-21-hemisuccinate was pre-
pared and conjugated to bovine serum albumin according 
to the method of Erlanger et al [5]. Male white rabbits 
were immunized by multiple intradermal injections of 
the steroid albumin conjugate suspended in complete 
Freund's adjuvant. Booster injections were given at 4- to 
5-week intervals. Antiserum obtained 4 months after 
immunization was used at a final dilution of 1: 14,000. 
Patient plasma (0.5 ml) was extracted twice with 4 ml of 
ethyl ether. The ether phase was then taken to dryness 
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under N 2 and redissolved in 0.4 ml of ethyl alcohol. The 
radioactive recovery after ether extraction was 94 ± 4 % 
(n = 11, mean ± SD) and no correction was made for 
procedural losses. Plasma extracts and standards were 
taken to dryness under N 2; 0.2 ml containing 2,000 dpm 
of [3H ]betamethasone 17 -benzoate (0.2 ng of the steroid) 
was added to each sample followed by 0 .5 ml of antiserum 
diluted to 1:10,000. The assay tubes were incubated for 18 
hr at 4 DC. Dextran-coated charcoal was used to separate 
bound from free steroid and the bound was counted in a 
liquid scintillation system . 
Intra-assay and interassay coefficient of variations 
were 6.4 and 13.6 %, respectively . Calculation of results 
was done by use of logit transformation [6] . Distilled 
water and plasma from subjects not receiving betametha-
sone 17 -benzoate consistently gave blanks which were 
less than 0.02 ng on the standard curve (percentage 
binding was more than 95 %) and they were defined as 
nondetectable. Plasma cortisol concentration was deter-
mined by radioimmunoassay [7]. 
Sixteen hospitalized patients were studied. Twelve 
were males and ages ranged from 17 to 83 years. The 
patients had atopic dermatitis, nummular eczema, pso-
riasis, and prurigo nodularis. Five, 10, or 20 gm of 0.025% 
betamethasone 17 -benzoate in cream or gel base (sup-
plied by Warner-Lambert Research Institute, N. J ., and 
Mitsui Pharmaceuticals Inc. , Japan) were applied evenly 
to the diseased skin, massaged into the skin as thoroughly 
as possible, and covered with plastic film. The dressing 
was left in place for 14 hr (6:00 PM to 8:00 AM). When the 
dressing was removed, the patients took a bath and the 
therapeutic response was recorded. The designated 
amount of cream or gel base without steroid was applied 
to the skin surface with occlusion for 4 days . Betametha-
sone 17 -benzoate was then applied with occlusion to the 
same sites for 7 days and the base only without occlusion 
for the following 3 days. Blood was collected on days 1, 4, 
7, 11, and 14 at 8:00 AM while patients were fasting. 
RESULTS 
Specificity of the antiserum is shown in Figure l. 
This antiserum was highly specific for betametha-
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sone 17-benzoate and showed only 0.005 % cross-
reactivity with cortisol. The useful range of the 
standard curve was established between 0.05 and 5 
ng (Fig. 2). 
Figure 3 illustrates plasma betamethasone 17-
benzoate and cortisol levels in 4 patients treated 
with betamethasone 17 -benzoate in cream or gel 
with occlusion. Plasma betamethasone 17-benzo-
ate levels were detected on days 7 and 11 when the 
steroid was applied. On days 1, 4, and 14, plasma 
betamethasone 17 -benzoate levels were non detect-
able. Plasma cortisol levels decreased at the 7th 
I (X) 
• 80 ,,-
hlraolol 1113 
ProCjp\ terone 
BetilOlPtha sone 
/ 17 · va lerate 
~IO-'----ILO'----~--~IO----~----L---~IO~' --~I~~ --~IO 
':> \ ( H II I 0 \ nq / IUbt' I 
FIG . 1. Cross-reactivity of various steroids with anti-
serum raised against betamethasone 17-benzoate-21-
hemisuccinate bovine serum albumin conjugate. 
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and 11th days. They returned to normal levels by 
the 14th day when the base without steroid was 
applied. 
To correlate plasma betamethasone 17 -benzoate 
levels and pituitary-adrenal suppression, the per-
cent inhibition of plasma cortisol is calculated 
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FIG. 2. Standard curve for betamethasone 17-benzoate 
radioimmunoassay. The abscissa is the log dose of un-
labeled steroid. The ordinate is the logit transform of 
counts bound and is = [(Bx -- N)/(Bo - N)] x 100, where 
Bx = counts bound at dose x, Bu = counts bound in the 
absence of added unlabeled steroid, and N = the nonspe-
cific counts bound. 
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FIG. 3. Plasma betamethasone 17-benzoate and cortisol levels in 4 patients treated with 10 and 20 gm of cream and 
gel base with occlusion. White column shows plasma betamethasone 17 -benzoate levels . ND means nondetectable. 
Open circles show plasma cortisol levels. Details are described under Materials and Methods. 
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TABLE. Plasma betamethasone 17-benzoate levels and percent inhibition of plasma cortisol on days 7 and 11 in 
patients treated with betamethasone 17-benzoate cream and gel base with occlusion 
Day7 Day 11 
Treatment Patient Plasma Percent Plasma Percent 
number betamethasone inhibition of betamethasone inhibition of 
17 -benzoate plasma 17-benzoate plasma 
(nglml) cortisola (nglml) cortisola 
Cream 1 0.41 43.1 0.34 0.4 
5 gm/day 2 0.49 19.3 0.66 11.9 
Cream 3 0.91 57.6 0.59 43.8 
10 gm/day 4 0.59 9.9 0.63 27.9 
5 1.26 58.4 1.38 85.8 
Cream 6 1.66 57.9 2.98 20.8 
20 gm/day 7 1.94 96.3 2.99 88.3 
8 2.16 35.8 2.53 91.2 
Gel 9 0.66 21.6 0.64 -2.4 
5 gm/day 10 1.17 42.5 1.69 43.8 
11 0.45 12.1 0.78 24.7 
Gel 12 2.17 23.3 1.76 60.5 
10 gm/day 13 2.37 57.1 2.54 73.4 
14 1.56 91.5 2.17 93.6 
Gel 15 3.97 91.6 4.89 92 .2 
20 gm/day 16 3.17 87 .0 2.67 85.7 
(100 x plasma cortisol on day 7 or 11) 
a Obtained by 100 ------------_______ _ 
(mean levels of plasma cortisol on days 1 and 4) 
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FIG. 4. Mean levels of plasma betamethasone 17-ben-
zoate and percent inhibition of plasma cortisol at days 7 
and 11 in patients treated with 5, 10, and 20 gm of cream 
and gel base with occlusion, respectively. The vertical 
bars indicate standard errors of the mean. 
(Tab.). Shown in Figure 4 are the mean levels of 
plasma betamethasone 17 -benzoate and the per-
cent inhibition of plasma cortisol on days 7 and 11 
in patients treated with 5, 10, and 20 gm of 
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FIG. 5. Correlation between plasma betamethasone 
17-benzoate levels and percent inhibition of plasma cor-
tisol. 'Y = 7038, Y = 19.0X + 18.5, p < 0.01. 
betamethasone 17 -benzoate cream and gel base 
with occlusion, respectively. Plasma betametha-
sone 17 -benzoate levels and the percent inhibition 
of plasma cortisol increased in proportion to the 
amount of the steroid applied to the skin. The data 
suggest that betamethasone 17 -benzoate in gel 
base was more readily absorbed than in cream 
base. When 20 gm of gel base was applied to the 
skin, the mean level of plasma betamethasone 
17 -benzoate was 3.68 ng/ml. This induced approxi-
mately 90% inhibition of plasma cortisol. 
When percent inhibition of plasma cortisol was 
plotted against plasma betamethasone 17 -benzo-
ate levels, a highly significant positive linear 
correlation was demonstrated (r = 0.7038, Y = 
19.0X + 18.5, p < 0.01) (Fig. 5). 
DISCUSSION 
The antiserum used was highly specific for 
betamethasone 17 -benzoate. All of the endogenous 
steroids tested cross-reacted less than 0.01 %, indi-
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cating that none of these steroids is present in 
sufficient concentrations in plasma to interfere 
with the determination of betamethasone 17 -ben-
zoate. 
Studies on percutaneous absorption of a drug are 
complex and involve numerous factors that include 
the base in which the drug is incorporated, the 
condition of the epidermal barrier, the size of area 
of application, the presence or absence of occlu-
sion, and so on. Serum steroid levels represent 
parameters of the flow of drug from the skin 
surface to excretion but not the absolute amount 
which has been absorbed. The data obtained 
suggest that there were marked differences 
between patients in percutaneous absorption of 
betamethasone 17-benzoate. Plasma betametha-
sone 17-benzoate levels were between 0.3 and 5 
ng/ml, indicating that approximately 0.05 to 0.3% 
of the steroid applied to the skin was detected in 
plasma. A relationship between the amount of the 
steroid applied to the skin and plasma betametha-
sone 17 -benzoate levels was observed. 
Pituitary-adrenal suppression and decreases in 
endogenous cortisol levels in patients following 
topical application of corticosteroids have been 
observed [8]. Our results show that betamethasone 
17 -benzoate induced temporary adrenocortical 
suppression in proportion to the amount of the 
Vol. 67, No.2 
steroid applied to patients. A high correlation 
between plasma betamethasone 17 -benzoate levels 
and percent inhibition of plasma cortisol was 
observed. Approximately 3 ng/ml of betametha-
sone 17 -benzoate in plasma induced 90% inhibition 
of plasma cortisol. 
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